PMC:7561592 / 17105-18230 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7561592","sourcedb":"PMC","sourceid":"7561592","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7561592","text":"The chromatographic methods used for drug analysis were modifications of published methods (31,32). Drug quantification was performed with HPLC with ultraviolet (UV) detection (Agilent HPLC system 1100/1200 series; Agilent, USA). A RP Agilent Eclipse XDB C18 column (250 mm × 4.6 mm, 5-μm particle size) was used for both drugs. For montelukast, the mobile phase was composed of ammonium acetate buffer pH 5.5 and methanol (solvents A and B, respectively) delivered at a flow rate of 1 mL min−1, on a linear gradient. The selected gradient started with 10% of solvent B, which was increased to 50% within 2 min, and 90% within 4 min; at 11.30 min, the initial conditions of analysis were re-established. Injection volume was 100 μL. Analysis was performed at 20°C and the detection wavelength was 284 nm. Elution time for montelukast was 8.9 min. For analysis of mesalazine, the mobile phase was composed of 0.05% TFA/water and methanol (95:5), delivered at a flow rate of 1 mL min−1. Injection volume was 20 μL. Analysis was performed at 40°C and the detection wavelength was 304 nm. Elution time for mesalazine was 4.6 min.","tracks":[{"project":"2_test","denotations":[{"id":"33063245-20726533-28138","span":{"begin":95,"end":97},"obj":"20726533"}],"attributes":[{"subj":"33063245-20726533-28138","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93caec","default":true}]}]}}